

TABLE I. Demographic, serologic, and clinical characterization of study subjects

Patients' characteristics		Symptomatic (n = 33)	Nonsymptomatic (n = 41)
Sex	Male/female	20/13	32/9
Age	Median (y [range])	2.3 (0.7-16.3)	2.0 (0.6-10.3)
Total IgE	Median (kU/L [range])	1,282 (29-22,300)	900 (15-15,360)
Specific IgE to soybean	Median (kU _A /L [range])	17.1 (0.36-92)	3.6 (0.54-77.3)
Diagnosis of soybean allergy	Oral food challenge	29	22
	History	4	19
Graded symptoms	Severe/mild*	14/19	—
Symptoms after challenge or intake (severe/mild)	Skin	11/19	—
	Mucosal	2/3	—
	Respiratory	12/0	—
	Gastrointestinal	3/0	—

Symptoms after challenge or intake are specified in the symptomatic children.

*Severe symptoms are defined as a combination of skin, respiratory, or gastrointestinal symptoms, and mild symptoms are defined as isolated skin symptoms, oral symptoms, or both.




FIG 1. Quantitative IgE measurement for soybean, Gly m 5, and Gly m 6. Comparison of IgE antibody levels between children with severe symptoms, mild symptoms, and no symptoms is shown. The Mann-Whitney *U* test (2-tail) was used to compare the statistical differences between the study groups, and significant differences are indicated as follows: **P* < .05, ***P* < .01, and ****P* < .001.

Of the 5 soybean allergens included in the multiplex assay, only the 2 storage proteins Gly m 5 and Gly m 6 were defined as major allergens. In fact, when using the more sensitive ImmunoCAP system, it was found that all children in the symptomatic group had IgE to Gly m 5 and Gly m 6. Holzhauser et al⁴ also found a large number of subjects with IgE antibodies to the same 2 proteins in European children and adults with soybean allergy, but they were not considered to be major allergens in their study group. The reason for Gly m 5 and Gly m 6 being found as major allergens in the present study might be the study group composition of children only or might depend on Japanese eating habits, with soybean being part of the daily food intake.

We found that IgE levels to Gly m 5, but not to Gly m 6, were significantly higher in the symptomatic group when compared with those in the nonsymptomatic group. Because of the significant overlap of individual values between the symptomatic and nonsymptomatic groups, it was not possible to decide on a predictive IgE level for clinical symptoms. In earlier studies Sampson¹ showed that the positive predictive level for specific IgE to soybean was estimated at 30 kU_A/L, and Komata et al⁹ showed an association between the level of IgE to soybean and positive challenge outcomes for soybean. In the present study it

was shown that increasing IgE levels to both soybean and Gly m 5 correlated with increasing risk for clinical reactions.

Significant differences between the IgE levels to Gly m 5 and Gly m 6 were seen between the group of children with severe symptoms and the nonsymptomatic children. A similar trend was seen in the study by Holzhauser et al,⁴ in which severe symptoms correlated with the presence of IgE to Gly m 5 and Gly m 6.

It is worthwhile noting that measurement of IgE levels to soybean extract provides the best differentiation between the symptomatic and nonsymptomatic groups. This is also true after dividing the symptomatic group into subjects with severe and mild symptoms. The major constituents in the soybean extract are the 2 storage proteins Gly m 5 and Gly m 6, and there was also a very good correlation between the IgE levels to soybean and those 2 proteins. Nevertheless, this might reflect that there are other nonidentified components present in the soybean extract to which IgE might have a predictive value. However, the well-recognized problem with IgE analysis based on soybean extract is the poor sensitivity, probably because of the presence of cross-reacting IgE antibodies primarily induced to allergens from other allergen sources, such as pollen, resulting in many sensitized subjects without symptoms from

soybean.^{1,10} Analysis of IgE antibodies to Gly m 5 and Gly m 6 will therefore most likely better predict soybean allergy than an extract-based test.

Interpretation of the severity of allergic symptoms through the level of sensitization is a complex matter, but this risk assessment is of great importance for the prediction of severe and potentially fatal reactions. In this study the levels of IgE responses to Gly m 5 and Gly m 6 were found to be associated with severe clinical reactions caused by soybean in Japanese children.

We thank Magnus Sundberg for help with the purification of Gly m 5 and Gly m 6 and Fredrik Bernhardsson for help with the running of the immunoassays.

Komei Ito, MD, PhD^a
Sigrid Sjölander, PhD^b
Sakura Sato, MD^c
Robert Movérare, PhD^{b,d}
Akira Tanaka, MSc^e
Lars Söderström, MSc^b
Magnus Borres, MD, PhD^{b,f}
Maryam Poorafshar, PhD^b
Motohiro Ebisawa, MD, PhD^c

From ^athe Department of Allergy, Aichi Children's Health and Medical Center, Obu, Japan; ^bPhadia AB, Uppsala, Sweden; ^cthe Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan; ^dthe Department of Medical Sciences, Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden; ^ePhadia KK, Tokyo, Japan; and ^fthe Department of Pediatrics, Sahlgrenska Academy of Gothenburg University, Gothenburg, Sweden. E-mail: koumei_ito@mx.achmc.pref.aichi.jp.

The data collection of this study was funded by Health and Labor Sciences Research Grants for Research on Allergic Disease and Immunology from the Japanese Ministry of Health, Labour and Welfare.

Disclosure of potential conflict of interest: S. Sjölander, R. Movérare, L. Söderström, and M. Borres are employees of Phadia AB. A. Tanaka is an employee of Phadia K.K. Japan. M. Poorafshar is an employee of Thermo Fisher. The rest of the authors have declared that they have no conflict of interest.

REFERENCES

1. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. *J Allergy Clin Immunol* 2001;107:891-6.
2. Ikematsu K, Tachimoto H, Sugisaki C, Syukuya A, Ebisawa M. Feature of food allergy developed during infancy (2)-acquisition of tolerance against hen's egg, cow's milk, wheat, and soybean up to 3 years old. *Alerugi* 2006;55:533-41.
3. Imamura T, Kanagawa Y, Ebisawa M. A survey of patients with self-reported severe food allergies in Japan. *Pediatr Allergy Immunol* 2008;19:270-4.
4. Holzhauser T, Wackermann O, Ballmer-Weber BK, Bindslev-Jensen C, Scibilia J, Perono-Garoffo L, et al. Soybean (Glycine max) allergy in Europe: Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin) are potential diagnostic markers for severe allergic reactions to soy. *J Allergy Clin Immunol* 2009;123:452-8.
5. Ballmer-Weber BK, Vieths S. Soy allergy in perspective. *Curr Opin Allergy Clin Immunol* 2008;8:270-5.
6. Ito K, Urisu A. Diagnosis of food allergy based on oral food challenge test. *Allergol Int* 2009;58:467-74.
7. Adachi A, Horikawa T, Shimizu H, Sarayama Y, Ogawa T, Sjölander S, et al. Soybean beta-conglycinin as the main allergen in a patient with food-dependent exercise-induced anaphylaxis by tofu: food processing alters pepsin resistance. *Clin Exp Allergy* 2009;39:167-73.
8. Thanh VH, Shibasaki K. Major proteins of soybean seeds. A straightforward fractionation and their characterization. *J Agric Food Chem* 1976;24:1117-21.
9. Komata T, Soderstrom L, Borres MP, Tachimoto H, Ebisawa M. Usefulness of wheat and soybean specific IgE antibody titers for the diagnosis of food allergy. *Allergol Int* 2009;58:599-603.
10. Matricardi PM, Bockelbrink A, Beyer K, Keil T, Niggemann B, Grüber C, et al. Primary versus secondary immunoglobulin E sensitization to soy and wheat in the Multi-Centre Allergy Study cohort. *Clin Exp Allergy* 2008;38:493-500.

Available online May 8, 2011.
doi:10.1016/j.jaci.2011.04.025

TNF- α blockade in chronic granulomatous disease-induced hyperinflammation: Patient analysis and murine model

To the Editor:

Chronic granulomatous disease (CGD), a genetic deficiency in the phagocyte nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2), leads to severe recurrent infections but also to exuberant inflammatory responses. Because infections have a major effect on mortality, they have been the main focus of CGD research and therapies, resulting in markedly increased survival. Because of the improved management of infections, inflammatory complications are now an increasingly important problem. Almost any organ can be affected, with the gut being probably the most common site.^{1,2} Although hyperinflammation might not lead to a major increase in mortality, it is associated with high morbidity.

A breakthrough in research on CGD-induced hyperinflammation was the generation of Nox2-deficient mice with CGD, leading to the development of a skin model of inflammatory complications by Dinauer.⁴ Indeed, injection of sterile fungal cell wall and more specifically β -glucan into the skin of mice with CGD leads to massive hyperinflammation and ultimately granuloma formation.^{4,5} Note that injection of sterile bacterial cell wall components did not lead to hyperinflammation.⁵ Underlying mechanisms are still poorly understood; however, a common observation is an increase in levels of proinflammatory cytokines, particularly TNF- α ,^{6,7} which is often cited as a possible culprit in CGD-induced inflammatory states.³

The following lines of argument suggest that TNF- α inhibition might be a pertinent treatment approach: (1) inflammatory cells from patients with CGD release increased amounts of proinflammatory cytokines, particularly TNF- α ; (2) anti-TNF- α treatments have been successfully used in other types of inflammatory diseases (eg, rheumatoid arthritis and Crohn disease); and (3) inflammatory complications in the context of other immunodeficiencies are improved by TNF- α blockers. However, it is not clear whether the increased secretion of TNF- α by leukocytes from patients with CGD is a causative mechanism in hyperinflammation. Yet despite the lack of information about the role of TNF- α in CGD-induced hyperinflammation, there is an increasing off-label use of anti-TNF- α treatments in patients with CGD. Indeed, the use of these compounds in the treatment of CGD-induced inflammatory complications has been suggested in several publications and is included in recent algorithms of CGD management. In fact, short-term treatment with infliximab has been proposed as the second-line treatment in patients with steroid-refractory chronic granulomatous colitis.⁸

We first performed a literature review on the treatment of CGD-induced inflammatory complications with TNF- α inhibitors (see Table E1 in this article's Online Repository at www.jacionline.org). We found indications for off-label use of TNF- α inhibitors in patients with CGD; indeed, we could identify a total of 17 published cases. Patients with autosomal recessive mutations are overrepresented in the collection (11/17 [65%]), and 7 of these presented with inflammatory bowel disease or arthritis as initial symptom (see patients marked by asterisks in Table E1). Note that in general autosomal recessive mutations represent approximately 30% of patients with CGD. Only in 5 patients was a clear and sustained response to treatment observed. The treatment response seemed genotype dependent: 4 (36%) of 11 autosomal

This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

The usefulness of casein-specific IgE and IgG4 antibodies in cow's milk allergic children

Clinical and Molecular Allergy 2012, **10**:1 doi:10.1186/1476-7961-10-1

Komei Ito (koumei_ito@mx.achmc.pref.aichi.jp)
Masaki Futamura (futamura-m@ncchd.go.jp)
Robert Moverare (robert.moverare@thermofisher.com)
Akira Tanaka (akira.tanaka@thermofisher.com)
Tutomu Kawabe (kawabe@met.nagoya-u.ac.jp)
Tatsuo Sakamoto (sakamoto@yamaguchi-u.ac.jp)
Magnus P Borres (magnus.borres@thermofisher.com)

ISSN 1476-7961

Article type Research

Submission date 20 September 2011

Acceptance date 2 January 2012

Publication date 2 January 2012

Article URL <http://www.clinicalmolecularallergy.com/content/10/1/1>

This peer-reviewed article was published immediately upon acceptance. It can be downloaded, printed and distributed freely for any purposes (see copyright notice below).

Articles in *CMA* are listed in PubMed and archived at PubMed Central.

For information about publishing your research in *CMA* or any BioMed Central journal, go to

<http://www.clinicalmolecularallergy.com/authors/instructions/>

For information about other BioMed Central publications go to

<http://www.biomedcentral.com/>

© 2012 Ito *et al.*; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The usefulness of casein-specific IgE and IgG4 antibodies in cow's milk allergic children

Komei Ito¹, Masaki Futamura^{1, 2}, Robert Movérare^{3, 4}, Akira Tanaka⁵, Tsutomu Kawabe⁶,
Tatsuo Sakamoto⁷, Magnus P Borres^{3, 8}

¹ Department of Allergy, Aichi Children's Health and Medical Center, Obu, Japan

² Division of Allergy, National Center for Child Health and Development, Tokyo, Japan

³ Phadia AB (now Thermo Fisher Scientific), Uppsala, Sweden

⁴ Department of Medical Sciences, Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden

⁵ Phadia KK (now Thermo Fisher Scientific), Tokyo, Japan

⁶ Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan

⁷ Department of Hygiene, Yamaguchi University Graduate School of Medicine, Ube, Japan

⁸ Department of Pediatrics, Sahlgrenska Academy of Göteborg University, Göteborg, Sweden

Corresponding author and requests for reprints:

Komei Ito, MD

Department of Allergy, Aichi Children's Health and Medical Center

1-2 Osakada, Morioka, Obu, Aichi 474-8710, JAPAN

E-mail: koumei_ito@mx.achmc.pref.aichi.jp

Telephone number: +81-562-43-0500

Fax number: +81- 562-43-0513

E-mail addresses of all authors:

Komei Ito koumei_ito@mx.achmc.pref.aichi.jp

Masaki Futamura futamura-m@ncchd.go.jp

Robert Movérare robert.moverare@thermofisher.com

Akira Tanaka akira.tanaka@thermofisher.com

Tsutomu Kawabe kawabe@met.nagoya-u.ac.jp

Tatsuo Sakamoto sakamoto@yamaguchi-u.ac.jp

Magnus P. Borres magnus.borres@thermofisher.com

Abstract

Background: Cow's milk allergy is one of the most common food allergies among younger children. We investigated IgE antibodies to milk, and IgE and IgG4 antibodies to casein, α -lactalbumin and β -lactoglobulin in cow's milk allergic (CMA) and non-allergic (non-CMA) children in order to study their clinical usefulness.

Methods: Eighty-three children with suspected milk allergy (median age: 3.5 years, range: 0.8-15.8 years) were diagnosed as CMA (n=61) or non-CMA (n=22) based on an open milk challenge or convincing clinical history. Their serum concentrations of allergen-specific (s) IgE and IgG4 antibodies were measured using ImmunoCAP[®]. For the sIgG4 analysis, 28 atopic and 31 non-atopic control children were additionally included (all non-milk sensitized).

Results: The CMA group had significantly higher levels of milk-, casein- and β -lactoglobulin-sIgE antibodies as compared to the non-CMA group. The casein test showed the best discriminating performance with a clinical decision point of 6.6 kU_A/L corresponding to 100% specificity. All but one of the CMA children aged >5 years had casein-sIgE levels >6.6 kU_A/L. The non-CMA group had significantly higher sIgG4 levels against all three milk allergens compared to the CMA group. This was most pronounced for casein-sIgG4 in non-CMA children without history of previous milk allergy. These children had significantly higher casein-sIgG4 levels compared to any other group, including the non-milk sensitized control children.

Conclusions: High levels of casein-sIgE antibodies are strongly associated with milk allergy in children and might be associated with prolonged allergy. Elevated casein-

sIgG4 levels in milk-sensitized individuals on normal diet indicate a modified Th2 response. However, the protective role of IgG4 antibodies in milk allergy is unclear.

Keywords: casein, cow's milk allergy, IgE, IgG4, ImmunoCAP

Background

Food allergies, described as adverse immune responses to food, are common and have increased in prevalence during the past decades. About 5% of the young children and 3-4% of the adults are affected today [1]. Milk, egg, peanut, tree nuts, fish, shellfish, wheat and soy are considered to cause most of the food adverse reactions [1]. Of these, cow's milk is the most frequent food causing allergy among infants and young children with a prevalence ranging from 1 to about 7.5% [2,3]. Proper management of milk allergy is important due to the low but serious risk of anaphylaxis [4]. Fortunately most children recover spontaneously from their allergy and develop tolerance to cow's milk until they reach 5 years of age [5,6]. The remaining children may have a prolonged cow's milk allergy causing discomfort and limitations to their daily lives for many years [7]. A recent study indicates that the proportion of children with prolonged milk allergy might be larger than previously anticipated [8].

The most important allergens in cow's milk are α -lactalbumin (also called Bos d 4), β -lactoglobulin (Bos d 5) and casein (Bos d 8) [2,9]. Milk can be separated into two fractions, the whey and the coagulum. Most known milk allergens are found in the milk whey including α -lactalbumin and β -lactoglobulin, while casein is present in the coagulum. Casein has been shown to be both more antigenic and allergenic than the whey proteins indicating its role as important milk allergen [10]. However, all milk proteins appear to be potential allergens and patients are often sensitized to several of them [11]. It has been shown that patients that are sensitized to several milk allergens tends to have a poor prognosis regarding outgrown of their milk allergy [12].

Diagnosis and management of food allergy include steps like initial avoidance of the suspected food allergen, skin prick testing and measuring of serum levels of food-specific IgE antibodies mostly using extract-based tests. In time, in order to confirm the diagnosis or to determine whether a reintroduction of the particular food is safe due to tolerance development, oral food challenges could be conducted [4]. Other diagnostic tools making it possible to earlier discriminate between prolonged and tolerated food allergies are desirable. We have earlier shown in wheat and egg allergy that specific IgE measurements could help the physician to provide better guidance to their patients and be a complement to food challenges [13,14].

Here, in order to study the clinical usefulness of specific antibodies in milk allergy, the concentrations of IgE antibodies to milk, and IgE and IgG4 antibodies to casein, α -lactalbumin and β -lactoglobulin were studied in sera from milk allergic and milk tolerant children.

Methods

Subjects

Eighty-three children with a suspected IgE-mediated cow's milk allergy (CMA) were enrolled in the study. The patients (male/female ratio, 55/28) ranged in age from 0.8 to 15.8 years (median: 3.5 years). All were milk sensitized as revealed by specific IgE *in vitro* test (n=81), or had a history of positive skin prick test to milk (n=2). Most of them suffered from atopic dermatitis (85%) and some also from asthma (32%). The patients were divided into two groups on the basis of their immediate reactions to an open oral milk provocation challenge test or through their case history. The cow's milk allergic (CMA) group (n=61) had either a positive challenge result for milk (n=34) or a convincing history of present milk allergy making a challenge test redundant (n=27). The non-CMA group (n=22) contained children who had no allergic reactions to milk at the time of examination. A subgroup of them had obtained tolerance after a previous diagnosed milk allergy (Tolerant, n=11) which was verified with a negative challenge test with milk. The remaining children had never had a milk allergy diagnosis (Negative, n=11). Further details about the study groups are found in Table 1.

For the specific IgG₄ analyses, a non-milk sensitized control group was included consisting of children that consulted our allergy clinic due to eczema, urticaria, bronchial asthma or any suspicion of allergic diseases and were examined for the following specific IgE antibodies; milk, *Dermatophagoides pteronyssinus*, cat dander, egg white, wheat, orchard grass, and Japanese cedar. Those who had no clinical history of milk allergy and without milk-specific IgE antibodies (<0.35 kU_A/L) were selected, and subsequently

divided into the following two subgroups. One subgroup consisted of 31 non-atopic controls (NAC; median age: 1.0 years, range: 0.8-6 years). They had low total IgE levels (median: 13.0 kU/L, range: 2.0-29.0 kU/L) and were negative to all of the specific IgE antibodies examined. The other subgroup consisted of 28 atopic controls (AC; median age: 5.0 years, range: 1-15 years). They were sensitized to at least one of the allergens described above, except milk, and had a median total IgE level of 928 kU/L (range: 254-4,618 kU/L).

Informed consent was obtained from patients, their parents, or both. The study was approved by the Ethics Committee of Fujita Health University School of Medicine.

Oral milk challenge

Open oral milk provocation tests were carried out as described in a Japanese guideline [15]. The children were orally challenged with raw milk, starting with one drop and followed with increasing volumes (1, 2, 5, 10, 20 or 30 ml) every 20 minutes, until a reaction was observed. Only objective immediate reactions were considered as positive results and the patients were given relevant relief medication thereafter. All provocation tests were conducted by qualified medical personnel.

Serological analysis

Serum levels of total IgE, IgE antibodies to milk, casein, α -lactalbumin and β -lactoglobulin, and IgG4 antibodies to casein, α -lactalbumin and β -lactoglobulin were measured using ImmunoCAP[®] (Phadia AB, Uppsala, Sweden). The commercially

available tests and reagents were used according to the instructions from the manufacturer.

Statistical analysis

The Mann-Whitney U-test (two-tailed) was used for comparisons between the groups and p values < 0.05 were considered significant. Receiver operating characteristic (ROC) analysis was performed for the different milk allergen ImmunoCAP tests used for specific IgE measurement [16]. Before statistical evaluation, all specific IgE values below the assay cut off (0.35 kU_A/L) were assigned a value of 0.34 kU_A/L, and all values above 100 kU_A/L (higher limit of quantitation) were assigned a value of 101 kU_A/L. In the same way, all specific IgG4 levels below the assay cut off (0.07 mg_A/L) were assigned a value of 0.06 mg_A/L.

Results

Milk allergen-specific IgE antibodies

No significant differences in total IgE levels between the CMA and non-CMA groups were seen (Table 1), while the CMA group had significant higher levels of milk-specific IgE antibodies as compared to the non-CMA group (Figure 1). Two children were negative for milk-specific serum IgE antibodies (<0.35 kU_A/L), but had a history of positive skin prick tests with wheal diameters of 12x4 and 15x9 mm, respectively.

The CMA patients had increased levels of casein-specific IgE antibodies as compared to the non-CMA patients. All but one CMA patient had casein-specific IgE >0.35 kU_A/L resulting in a 98% sensitivity for the casein ImmunoCAP test using the traditional assay cut off. The levels of β -lactoglobulin-specific IgE were also increased in the CMA group, but no differences between the groups were seen for α -lactalbumin-specific IgE. There were 19 patients without measurable β -lactoglobulin-specific IgE (<0.35 kU_A/L) and 30 patients without α -lactalbumin-specific IgE, resulting in clinical sensitivity values of 69% for the β -lactoglobulin test and 51% for the α -lactalbumin test, respectively (Figure 1).

The ROC analysis showed that the casein ImmunoCAP test was superior in its diagnostic performance compared to the milk, α -lactalbumin and β -lactoglobulin tests (Figure 2). It was especially outstanding in its clinical specificity. The ROC analysis for the casein ImmunoCAP test showed that, when using a clinical decision point corresponding to 6.6 kU_A/L of casein-specific IgE, a specificity of 100% and a sensitivity of 72% could be achieved. At corresponding cut-off points with 100% clinical specificity, the milk and β -

lactoglobulin tests showed clinical sensitivity values of just 33% and 11%, respectively. Using the α -lactalbumin ImmunoCAP test, a specificity of no better than 63% could be achieved in this patient material. No children with casein-specific IgE below the clinical decision point of 6.6 kU_A/L had high levels of IgE antibodies to milk, β -lactoglobulin or α -lactalbumin.

Tolerance for cow's milk is expected to be obtained until the age of five years for most allergic children [5,6]. When looking at the subgroup of children over five years of age, all but one of the CMA children had casein-specific IgE concentrations above our suggested positive prediction point of 6.6 kU_A/L, while all of the older non-CMA children had lower levels (Figure 3). Also the IgE levels to milk and β -lactoglobulin were significantly elevated in CMA children compared to non-CMA children over five years of age, although not as prominent as for the casein-specific IgE (data not shown).

Milk allergen-specific IgG4 antibodies

The serum levels of casein-, α -lactalbumin- and β -lactoglobulin-specific IgG4 antibodies were measured in the CMA and non-CMA groups as well as in a non-milk sensitized control group consisting of children with (AC subgroup) and without atopy (NAC subgroup) as defined by their sensitization to common inhalant and/or food allergens.

The non-CMA group had significantly increased levels of specific IgG4 antibodies to all three milk allergens as compared to the CMA group ($p < 0.01$ and < 0.001). However, when studying the Tolerant and Negative subgroups of the non-CMA group individually,

it was shown that the increased levels of specific IgG4 were seen mainly in the Negative subgroup composed of children without previous history of milk allergy (Table 2).

Increased levels of specific IgG4 to α -lactalbumin- and β -lactoglobulin were also seen in the non-milk sensitized control group. However, increased levels of casein-specific IgG4 antibodies, as compared to the CMA group, were only found in the AC subgroup (Table 2). The overall highest levels of casein-specific IgG4 were observed in the Negative subgroup of children belonging to the non-CMA group followed in rank by the AC subgroup ($p < 0.05$) and the NAC subgroup ($p < 0.001$). The casein-specific IgG4 levels in the NAC subgroup were similar as in the CMA group and the Tolerant subgroup.

Discussion

In the present study, it was shown that the levels of IgE antibodies to milk, casein and β -lactoglobulin were increased in Japanese children with milk allergy compared to milk-sensitized children without present symptoms to milk (non-CMA children). When comparing different ImmunoCAP tests for measurement of IgE antibodies to milk, casein, α -lactalbumin and β -lactoglobulin, the best performance in the diagnosis of milk allergy was shown for the casein test. All but one of the CMA children had casein-specific IgE antibodies (>0.35 kU_A/L). A majority of them (72%) had casein-specific IgE antibodies above our suggested clinical decision point of 6.6 kU_A/L, while all non-CMA children were below this cut-off point for casein-specific IgE.

Milk allergy is an obvious health problem and burden for the individual allergic child. But the disease also causes limitations to the daily life of the immediate family in their effort of trying to avoid accidental exposure of their child to milk. A recent study showed that allergic reactions to accidental exposure to milk allergens indeed are frequent [17]. Avoiding casein and other cow's milk allergens might not always be so simple or feasible considering that all kinds of foods and dairy products may not have the proper labeling of the contents. Allergic reactions have also been reported as a result of casein being added as an extender to non-dairy products such as sausages and soups [18].

Double-blind, placebo-controlled food challenge is considered to be the gold standard for food allergy diagnosis, although it carries some risks for the patient and is time-consuming to conduct [15]. For several reasons many children are diagnosed as having a

food allergy even though no food challenges are performed [4]. This may lead to an over-diagnosis that is very costly for the society. Even more important, it is negatively influencing the quality of life for the whole family that is concerned [19]. Serious food allergies may also be missed. Therefore, improved diagnostic tools including better knowledge how to interpret test results are crucial. For several years studies have been performed by leading allergologists to find clinical decision points for the diagnosis of food allergy using allergen-specific serum IgE measurements. Cut-off points for clinical milk allergy in 2-3 year old children have been reported by others to be 24 kU_A/L for IgE antibodies to milk and 9 kU_A/L for IgE to casein, respectively [20]. Thus, a similar decision point for the casein-specific IgE as found in the present study with Japanese children with a median age of 3.5 years. However, clinical decision points often varies between studies which can be explained by differences between the study populations and the statistical criteria for choosing the decision points [21]. For example, younger children generally have lower levels of IgE antibodies to milk compared to older children [20,22], something that has to be acknowledged when interpreting specific IgE test results in the diagnosis of children.

Studies have shown that milk-specific IgE levels are lower in children who later become tolerant than in those with prolonged allergy, showing that IgE antibody measurements can be used to predict tolerance development [8,23,24]. In our study, the levels of specific IgE to milk, casein and β -lactoglobulin were elevated in patients diagnosed with prolonged milk allergy (defined as having milk allergy at age >5 years) as compared to milk-tolerant patients at similar age. Again, the casein test showed an excellent diagnostic

performance, since all but one of the CMA children had casein-specific IgE levels above our suggested positive prediction point of 6.6 kU_A/L. Also others have shown that patients with prolonged milk allergy generally have higher levels of milk-specific IgE than patients whose allergy has resolved [7,8], and the association between casein-specific IgE and prolonged milk allergy has been shown both in children [20,23] and in adults [25].

The production of IgG4 antibodies is considered to be a normal physiological response to the ingestion of cow's milk [26]. Previous studies have shown that individuals that tolerate cow's milk have higher levels of milk-specific IgG4 antibodies than those with a prolonged milk allergy [27,28], and it has been indicated that IgE and IgG4 antibodies combined might be used to predict tolerance development [29]. However, in our study the subgroup of non-CMA children who had obtained milk tolerance as diagnosed by challenge (Tolerant group) did not have significantly higher levels of casein-, α -lactalbumin- or β -lactoglobulin-specific IgG4 antibodies as compared to the CMA group, probably a consequence of their milk avoidance. Instead, the subgroup of children who never had had milk allergy, although sensitized to milk (Negative subgroup), showed elevated concentrations of IgG4 antibodies. This indicates that high levels of milk allergen-specific IgG4 antibodies are merely a reflection of a child's diet where cow's milk normally is included. So in line with the common opinion [30], our study supports that measurement of IgG4 antibodies has currently no role in the diagnosis of food allergy.

Interestingly, the Negative subgroup had the highest levels of casein-specific IgG4 of all groups in the study including the AC group and NAC group with non-milk sensitized children. It suggests that casein-specific IgG4 antibodies might be markers of a so-called modified Th2 response as suggested by Platts-Mills [31]. Thus, the milk allergen-specific IgG4 antibodies might have a protective role against the development of milk allergy, perhaps by blocking the antigen-presentation to allergen-specific T cells as described by others [32].

Conclusions

IgE antibody levels to milk, casein and β -lactoglobulin were increased in Japanese children with cow's milk allergy. The casein ImmunoCAP test showed the best clinical performance. A majority of the CMA children had casein-specific IgE levels above our suggested positive decision point of 6.6 kU_A/L, while all non-CMA children were below this cut-off point. It was also shown that the levels of casein-specific IgE remained high in CMA children also after five years of age. We therefore conclude that high levels of casein-specific IgE antibodies are strongly associated with milk allergy in children and might be associated with a prolonged allergy. Results from the present study indicate that high levels of casein-specific IgG4 antibodies are associated with tolerance in milk-sensitized children, but only in subjects on normal milk-containing diet. The protective role of IgG4 antibodies in a so-called modified Th2 response is unclear, and it has not yet been proven that measurement of IgG4 antibodies has a role in the clinical management of food allergy. Thus, more studies are needed before proposing routine use of specific IgG4 measurements in milk allergy.

Competing interests

The authors declare that they have no competing interest.

Authors' contributions

All authors have contributed to the final interpretation of data and the writing of the manuscript that has been approved by all parts. Furthermore, KI initiated and coordinated the Japanese part of the study. MF carried out sample collection. RM reviewed the results and coordinated the writing of the manuscript. AK coordinated the collaboration between Japan and Sweden. TK performed data analysis. TS supervised the study design and process. MB planned the Swedish part of the study including writing of manuscript.

Acknowledgements

The data collection of this study was funded by Health and Labor Sciences Research Grants for Research on Allergic Disease and Immunology from the Japanese Ministry of Health, Labour and Welfare.